{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T08:29:57Z","timestamp":1793608197835,"version":"4.5.0"},"reference-count":101,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Rheumatology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.berh.2026.102125","type":"journal-article","created":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T11:56:10Z","timestamp":1772366170000},"page":"102125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical assessment of Psoriatic Arthritis"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7890-6182","authenticated-orcid":false,"given":"James","family":"Kimpton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7531-4125","authenticated-orcid":false,"given":"William","family":"Tillett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.berh.2026.102125_bib1","doi-asserted-by":"crossref","first-page":"65","DOI":"10.7861\/clinmedicine.17-1-65","article-title":"Psoriatic arthritis: state of the art review","volume":"17","author":"Coates","year":"2017","journal-title":"Clin Med"},{"issue":"12","key":"10.1016\/j.berh.2026.102125_bib2","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1002\/acr.20627","article-title":"Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis","volume":"63","author":"Husted","year":"2011","journal-title":"Arthritis Care Res"},{"issue":"2","key":"10.1016\/j.berh.2026.102125_bib3","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/rheumatology\/ker216","article-title":"Work disability in psoriatic arthritis: a systematic review","volume":"51","author":"Tillett","year":"2012","journal-title":"Rheumatology (Oxford)"},{"issue":"10012","key":"10.1016\/j.berh.2026.102125_bib4","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1016\/S0140-6736(15)00347-5","article-title":"Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial","volume":"386","author":"Coates","year":"2015","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.berh.2026.102125_bib5","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1093\/rheumatology\/keac295","article-title":"The 2022 British society for rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs","volume":"61","author":"Tucker","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.berh.2026.102125_bib6","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/ard-2024-225531","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update","volume":"83","author":"Gossec","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.berh.2026.102125_bib7","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1002\/art.24562","article-title":"International multicenter psoriasis and psoriatic arthritis reliability trial for the assessment of skin, joints, nails, and dactylitis","volume":"61","author":"Chandran","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.berh.2026.102125_bib8","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.semarthrit.2016.06.004","article-title":"Impact of training on concordance among rheumatologists and dermatologists in the assessment of patients with psoriasis and psoriatic arthritis","volume":"46","author":"Salvarani","year":"2016","journal-title":"Semin Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.berh.2026.102125_bib9","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1093\/rheumatology\/kes095","article-title":"Joint count reliability in psoriatic arthritis observational trials--an unreported problem","volume":"51","author":"Tillett","year":"2012","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.berh.2026.102125_bib10","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1136\/annrheumdis-2016-210242","article-title":"International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials","volume":"76","author":"Orbai","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.berh.2026.102125_bib11","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2017-212004","article-title":"GRAPPA-OMERACT initiative to standardise outcomes in psoriatic arthritis clinical trials and longitudinal observational studies","volume":"77","author":"Tillett","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2026.102125_bib12","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/art.1780080214","article-title":"A seven-day variability study of 499 patients with peripheral rheumatoid arthritis","volume":"8","author":"Deandrade","year":"1965","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.berh.2026.102125_bib13","doi-asserted-by":"crossref","first-page":"996","DOI":"10.3899\/jrheum.181089","article-title":"Endorsement of the 66\/68 joint count for the measurement of musculoskeletal disease activity: OMERACT 2018 psoriatic arthritis workshop report","volume":"46","author":"Duarte-Garcia","year":"2019","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2026.102125_bib14","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.berh.2026.102125_bib15","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/art.37939","article-title":"Reduced joint counts misclassify patients with oligoarticular psoriatic arthritis and miss significant numbers of patients with active disease","volume":"65","author":"Coates","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.berh.2026.102125_bib16","doi-asserted-by":"crossref","DOI":"10.1186\/ar2327","article-title":"Ultrasonography, magnetic resonance imaging, radiography, and clinical assessment of inflammatory and destructive changes in fingers and toes of patients with psoriatic arthritis","volume":"9","author":"Wiell","year":"2007","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"10.1016\/j.berh.2026.102125_bib17","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1136\/annrheumdis-2012-203073","article-title":"Disparity between ultrasound and clinical findings in psoriatic arthritis","volume":"73","author":"Husic","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2026.102125_bib18","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.semarthrit.2017.12.008","article-title":"Enthesitis: a hallmark of psoriatic arthritis","volume":"48","author":"Kaeley","year":"2018","journal-title":"Semin Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.berh.2026.102125_bib19","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.berh.2026.102125_bib20","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/art.23568","article-title":"Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis","volume":"59","author":"Healy","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.berh.2026.102125_bib21","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1136\/ard.2007.084244","article-title":"Development and validation of the spondyloarthritis research consortium of Canada (SPARCC) Enthesitis index","volume":"68","author":"Maksymowych","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.berh.2026.102125_bib22","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.3899\/jrheum.140878","article-title":"Systematic review of treatment effectiveness and outcome measures for enthesitis in psoriatic arthritis","volume":"41","author":"Orbai","year":"2014","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.berh.2026.102125_bib23","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.semarthrit.2018.05.011","article-title":"Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study","volume":"48","author":"Araujo","year":"2019","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.berh.2026.102125_bib24","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/BOR.0000000000000388","article-title":"Fibromyalgia, a missed comorbidity in spondyloarthritis: prevalence and impact on assessment and treatment","volume":"29","author":"Mease","year":"2017","journal-title":"Curr Opin Rheumatol"},{"issue":"6","key":"10.1016\/j.berh.2026.102125_bib25","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/acr.23693","article-title":"Pain mechanisms and ultrasonic inflammatory activity as prognostic factors in patients with psoriatic arthritis: a prospective cohort study","volume":"71","author":"Hojgaard","year":"2019","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.berh.2026.102125_bib26","doi-asserted-by":"crossref","DOI":"10.5402\/2011\/731917","article-title":"Clinical and ultrasound examination of the leeds enthesitis index in psoriatic arthritis and rheumatoid arthritis","volume":"2011","author":"Ibrahim","year":"2011","journal-title":"ISRN Rheumatol"},{"issue":"2","key":"10.1016\/j.berh.2026.102125_bib27","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/art.10812","article-title":"Assessment of peripheral enthesitis in the spondylarthropathies by ultrasonography combined with power Doppler: a cross-sectional study","volume":"48","author":"D'Agostino","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.berh.2026.102125_bib28","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/art.42971","article-title":"Relationship between ultrasound and physical examination in the assessment of enthesitis in patients with spondyloarthritis: results from the DEUS multicenter study","volume":"77","author":"Di","year":"2025","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.berh.2026.102125_bib29","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.semarthrit.2018.02.002","article-title":"Dactylitis: a hallmark of psoriatic arthritis","volume":"48","author":"Kaeley","year":"2018","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.berh.2026.102125_bib30","first-page":"1302","article-title":"Measuring dactylitis in clinical trials: which is the best instrument to use?","volume":"34","author":"Healy","year":"2007","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2026.102125_bib31","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/annrheumdis-2013-203696","article-title":"Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)","volume":"73","author":"Mease","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.berh.2026.102125_bib32","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1093\/rheumatology\/kez629","article-title":"Axial disease in psoriatic arthritis","volume":"59","author":"Helliwell","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.berh.2026.102125_bib33","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X211057975","article-title":"Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)","volume":"13","author":"Poddubnyy","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"suppl 9","key":"10.1016\/j.berh.2026.102125_bib34","article-title":"Characteristics of patients with psoriatic arthritis presenting with axial involvement: results of a prospective international multicenter Study (AXIS) [abstract]","volume":"76","author":"Torgutalp","year":"2024","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2026.102125_bib35","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/acr.20017","article-title":"Validity of the bath ankylosing spondylitis disease activity index for the evaluation of disease activity in axial psoriatic arthritis","volume":"62","author":"Fernandez-Sueiro","year":"2010","journal-title":"Arthritis Care Res"},{"issue":"12","key":"10.1016\/j.berh.2026.102125_bib36","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1136\/ard.2008.100826","article-title":"ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis","volume":"68","author":"van der Heijde","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 5","key":"10.1016\/j.berh.2026.102125_bib37","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/jdv.12562","article-title":"Is there a psoriasis skin phenotype associated with psoriatic arthritis? Systematic literature review","volume":"28","author":"Rouzaud","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"Suppl 2","key":"10.1016\/j.berh.2026.102125_bib38","doi-asserted-by":"crossref","first-page":"ii65","DOI":"10.1136\/ard.2004.031237","article-title":"Psoriasis assessment tools in clinical trials","volume":"64","author":"Feldman","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 11","key":"10.1016\/j.berh.2026.102125_bib39","first-page":"S64","volume":"63","author":"Mease","year":"2011","journal-title":"Arthritis Care Res"},{"issue":"1","key":"10.1016\/j.berh.2026.102125_bib40","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3109\/09546634.2013.865009","article-title":"The 5-point Investigator's Global Assessment (IGA) Scale: a modified tool for evaluating plaque psoriasis severity in clinical trials","volume":"26","author":"Langley","year":"2015","journal-title":"J Dermatol Treat"},{"issue":"3","key":"10.1016\/j.berh.2026.102125_bib41","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jaad.2011.01.022","article-title":"Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis","volume":"66","author":"Robinson","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.berh.2026.102125_bib42","doi-asserted-by":"crossref","first-page":"851","DOI":"10.17219\/acem\/69804","article-title":"The reliability of three psoriasis assessment tools: psoriasis area and severity index, body surface area and physician global assessment","volume":"26","author":"Bozek","year":"2017","journal-title":"Adv Clin Exp Med"},{"key":"10.1016\/j.berh.2026.102125_bib43","first-page":"65","article-title":"The physician global assessment and body surface area composite tool is a simple alternative to the psoriasis area and severity index for assessment of psoriasis: post hoc analysis from PRISTINE and PRESTA","volume":"8","author":"Walsh","year":"2018","journal-title":"Psoriasis (Auckl)"},{"issue":"8","key":"10.1016\/j.berh.2026.102125_bib44","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.3899\/jrheum.201471","article-title":"Nail psoriasis: diagnosis, assessment, treatment options, and unmet clinical needs","volume":"48","author":"Kaeley","year":"2021","journal-title":"J Rheumatol"},{"issue":"9","key":"10.1016\/j.berh.2026.102125_bib45","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.3899\/jrheum.180796","article-title":"Psoriatic nail dystrophy is associated with erosive disease in the distal interphalangeal joints in psoriatic arthritis: a retrospective cohort study","volume":"46","author":"Antony","year":"2019","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.berh.2026.102125_bib46","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1067\/S0190-9622(03)00910-1","article-title":"Nail psoriasis severity index: a useful tool for evaluation of nail psoriasis","volume":"49","author":"Rich","year":"2003","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.berh.2026.102125_bib47","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1365-2230.2006.02305.x","article-title":"Interobserver reliability of the nail psoriasis severity index","volume":"32","author":"Aktan","year":"2007","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"10.1016\/j.berh.2026.102125_bib48","first-page":"123","article-title":"The modified nail psoriasis severity index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis","volume":"34","author":"Cassell","year":"2007","journal-title":"J Rheumatol"},{"issue":"suppl 10","key":"10.1016\/j.berh.2026.102125_bib49","article-title":"The \u2018Severity of Nail Psoriasis Score\u2019 (SNAPS) is feasible, reliable and demonstrates construct validity against the mNAPSI in an observational cohort of patients with psoriatic arthritis [abstract]","volume":"71","author":"Antony","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"10.1016\/j.berh.2026.102125_bib50","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.3899\/jrheum.2024-0152","article-title":"The development and validation of a novel training infographic for the physician global visual analog scale in psoriatic arthritis","volume":"51","author":"Gunawardana","year":"2024","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.berh.2026.102125_bib51","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s40271-017-0221-4","article-title":"Important treatment outcomes for patients with psoriatic arthritis: a multisite qualitative study","volume":"10","author":"Dures","year":"2017","journal-title":"Patient"},{"issue":"10","key":"10.1016\/j.berh.2026.102125_bib52","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.3899\/jrheum.141386","article-title":"Harmonizing pain outcome measures: results of the Pre-OMERACT meeting on partnerships for consensus on patient-important pain outcome domains between the Cochrane Musculoskeletal group and OMERACT","volume":"42","author":"Phillips","year":"2015","journal-title":"J Rheumatol"},{"issue":"9","key":"10.1016\/j.berh.2026.102125_bib53","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/acr.25358","article-title":"Prevalence of fibromyalgia and widespread pain in psoriatic arthritis: association with disease severity assessment in a large US registry","volume":"76","author":"Mease","year":"2024","journal-title":"Arthritis Care Res"},{"issue":"5","key":"10.1016\/j.berh.2026.102125_bib54","doi-asserted-by":"crossref","first-page":"898","DOI":"10.3899\/jrheum.100857","article-title":"Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study","volume":"38","author":"Cauli","year":"2011","journal-title":"J Rheumatol"},{"issue":"12","key":"10.1016\/j.berh.2026.102125_bib55","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.3899\/jrheum.150595","article-title":"Patient's global assessment as an outcome measure for psoriatic arthritis in clinical practice: a surrogate for measuring low disease activity?","volume":"42","author":"Lubrano","year":"2015","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.berh.2026.102125_bib56","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jbspin.2015.06.018","article-title":"Patient global assessment in psoriatic arthritis - what does it mean? An analysis of 223 patients from the Psoriatic arthritis impact of disease (PsAID) study","volume":"83","author":"Talli","year":"2016","journal-title":"Jt Bone Spine"},{"issue":"3","key":"10.1016\/j.berh.2026.102125_bib57","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3899\/jrheum.161544","article-title":"Composite measures of impact and activity in psoriatic arthritis: a conceptual framework","volume":"44","author":"Tillett","year":"2017","journal-title":"J Rheumatol"},{"issue":"Suppl 2","key":"10.1016\/j.berh.2026.102125_bib58","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3899\/jrheum.2023-0530","article-title":"Initiating evaluation of composite outcome measures for psoriatic arthritis: 2022 updates from the GRAPPA-OMERACT working group","volume":"50","author":"Leung","year":"2023","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1016\/j.berh.2026.102125_bib59","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.semarthrit.2021.07.014","article-title":"OMERACT Filter 2.1 instrument selection for physical function domain in psoriatic arthritis: provisional endorsement for HAQ-DI and SF-36 PF","volume":"51","author":"Leung","year":"2021","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.berh.2026.102125_bib60","first-page":"511","article-title":"Validating the SF-36 health survey questionnaire in patients with psoriatic arthritis","volume":"24","author":"Husted","year":"1997","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2026.102125_bib61","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3899\/jrheum.191119","article-title":"Appraisal of candidate instruments for assessment of the physical function domain in patients with psoriatic arthritis","volume":"48","author":"Leung","year":"2021","journal-title":"J Rheumatol"},{"key":"10.1016\/j.berh.2026.102125_bib62","article-title":"Determining the best discriminatory physical functioning outcome measurement instrument for psoriatic arthritis trials: a meta-epidemiological study","volume":"77","author":"Leung","year":"2025","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.berh.2026.102125_bib63","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1136\/annrheumdis-2014-205207","article-title":"A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative","volume":"73","author":"Gossec","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.berh.2026.102125_bib64","doi-asserted-by":"crossref","first-page":"990","DOI":"10.3899\/jrheum.181077","article-title":"PsAID12 provisionally endorsed at OMERACT 2018 as core outcome measure to assess psoriatic arthritis-specific health-related quality of life in clinical trials","volume":"46","author":"Orbai","year":"2019","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.berh.2026.102125_bib65","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1136\/annrheumdis-2017-211996","article-title":"Validation of the Psoriatic Arthritis Impact of Disease (PsAID) Questionnaire and its potential as a single-item outcome measure in clinical practice","volume":"77","author":"Holland","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2026.102125_bib66","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003548","article-title":"Validity and score interpretation of the 12-item Psoriatic Arthritis Impact of Disease: an analysis of pooled data from two phase 3 trials of bimekizumab in patients with psoriatic arthritis","volume":"10","author":"Gossec","year":"2024","journal-title":"RMD Open"},{"issue":"2","key":"10.1016\/j.berh.2026.102125_bib67","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1136\/ard.2003.006296","article-title":"Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis","volume":"63","author":"McKenna","year":"2004","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.berh.2026.102125_bib68","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001321","article-title":"Patient's experience of psoriatic arthritis: a conceptual model based on qualitative interviews","volume":"6","author":"Ogdie","year":"2020","journal-title":"RMD Open"},{"issue":"7","key":"10.1016\/j.berh.2026.102125_bib69","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1136\/ard.2006.065763","article-title":"Functional assessment of chronic illness therapy-fatigue scale is valid in patients with psoriatic arthritis","volume":"66","author":"Chandran","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.berh.2026.102125_bib70","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.semarthrit.2017.09.002","article-title":"A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: a GRAPPA-OMERACT initiative","volume":"47","author":"Hojgaard","year":"2018","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.berh.2026.102125_bib71","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-000928","article-title":"Fatigue numeric rating scale validity, discrimination and responder definition in patients with psoriatic arthritis","volume":"6","author":"Gladman","year":"2020","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.berh.2026.102125_bib72","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001756","article-title":"Systematic review of the use of CRP in clinical trials for psoriatic arthritis: a concern for clinical practice?","volume":"8","author":"Houttekiet","year":"2022","journal-title":"RMD Open"},{"issue":"3","key":"10.1016\/j.berh.2026.102125_bib73","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3899\/jrheum.180195","article-title":"Using acute-phase reactants to inform the development of instruments for the updated psoriatic arthritis core outcome measurement set","volume":"46","author":"Elmamoun","year":"2019","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2026.102125_bib74","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s40744-021-00420-x","article-title":"Usage of C-Reactive protein testing in the diagnosis and monitoring of psoriatic arthritis (PsA): results from a real-world survey in the USA and Europe","volume":"9","author":"Ogdie","year":"2022","journal-title":"Rheumatol Ther"},{"issue":"6","key":"10.1016\/j.berh.2026.102125_bib75","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.semarthrit.2021.11.001","article-title":"Composite outcomes at OMERACT: multi-outcome domains and composite outcome domains","volume":"51","author":"Wells","year":"2021","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.berh.2026.102125_bib84","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/ard.2008.102053","article-title":"Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment","volume":"69","author":"Coates","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.berh.2026.102125_bib85","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1136\/ard.2009.122259","article-title":"Application of the DAREA\/DAPSA score for assessment of disease activity in psoriatic arthritis","volume":"69","author":"Schoels","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.berh.2026.102125_bib80","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1136\/ard.2010.129379","article-title":"Development of a preliminary composite disease activity index in psoriatic arthritis","volume":"70","author":"Mumtaz","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.berh.2026.102125_bib81","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1136\/annrheumdis-2012-201341","article-title":"The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project)","volume":"72","author":"Helliwell","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2026.102125_bib90","first-page":"45","article-title":"Composite measures for routine clinical practice in psoriatic arthritis: testing of shortened versions in a UK multicenter study","volume":"97","author":"Tillett","year":"2021","journal-title":"J Rheumatol Suppl"},{"issue":"6","key":"10.1016\/j.berh.2026.102125_bib76","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American college of rheumatology. Preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.berh.2026.102125_bib77","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1136\/ard.2006.051706","article-title":"Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors","volume":"65","author":"Fransen","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"10370","key":"10.1016\/j.berh.2026.102125_bib78","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0140-6736(22)02302-9","article-title":"Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)","volume":"401","author":"McInnes","year":"2023","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.berh.2026.102125_bib79","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1002\/art.21306","article-title":"Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Mease","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2026.102125_bib82","doi-asserted-by":"crossref","DOI":"10.3899\/jrheum.2025-0268","article-title":"Composite outcome measures for psoriatic arthritis: project updates 2024","author":"Ribeiro","year":"2025","journal-title":"J Rheumatol"},{"issue":"12","key":"10.1016\/j.berh.2026.102125_bib83","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1093\/rheumatology\/kez254","article-title":"Implementing Psoriatic Arthritis Disease Activity Score-guided treat-to-target in psoriatic arthritis routine clinical practice: (im)possible?","volume":"58","author":"Mulder","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.berh.2026.102125_bib86","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","article-title":"Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force","volume":"77","author":"Smolen","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.berh.2026.102125_bib87","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.semarthrit.2020.03.015","article-title":"Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2-year results from the FUTURE 2 study","volume":"50","author":"Coates","year":"2020","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.berh.2026.102125_bib88","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1136\/annrheumdis-2017-211998","article-title":"Ideal target for psoriatic arthritis? Comparison of remission and low disease activity states in a real-life cohort","volume":"77","author":"van Mens","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.berh.2026.102125_bib89","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1002\/acr.23571","article-title":"Burden of psoriatic arthritis according to different definitions of disease activity: comparing minimal disease activity and the disease activity index for psoriatic arthritis","volume":"70","author":"Wervers","year":"2018","journal-title":"Arthritis Care Res"},{"issue":"Suppl 2","key":"10.1016\/j.berh.2026.102125_bib91","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3899\/jrheum.2024-0515","article-title":"Composite outcome measures for Psoriatic Arthritis: OMERACT and 3 and 4 visual analog scale progress in 2023","volume":"51","author":"Leung","year":"2024","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1016\/j.berh.2026.102125_bib92","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s40744-024-00690-1","article-title":"Filling the \"GAP\" in real-world assessment of psoriatic arthritis disease activity: performance characteristics of a global\/pain composite endpoint","volume":"11","author":"Tillett","year":"2024","journal-title":"Rheumatol Ther"},{"issue":"3","key":"10.1016\/j.berh.2026.102125_bib93","doi-asserted-by":"crossref","first-page":"e220","DOI":"10.1016\/S2665-9913(21)00349-0","article-title":"The state of the art-psoriatic arthritis outcome assessment in clinical trials and daily practice","volume":"4","author":"Day","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.berh.2026.102125_bib94","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3899\/jrheum.200121","article-title":"Outcomes of the 2019 GRAPPA workshop on continuous composite indices for the assessment of psoriatic arthritis and membership-recommended next steps","volume":"96","author":"Tillett","year":"2020","journal-title":"J Rheumatol Suppl"},{"issue":"7","key":"10.1016\/j.berh.2026.102125_bib95","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0253615","article-title":"Electronic patient-reported outcome measures using mobile health technology in rheumatology: a scoping review","volume":"16","author":"Shelton","year":"2021","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.berh.2026.102125_bib96","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1002\/art.42559","article-title":"The clinical impact of electronic patient-reported outcome measures in the remote monitoring of inflammatory arthritis: a systematic review and meta-analysis","volume":"75","author":"Arumalla","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2026.102125_bib97","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1186\/s13063-024-08497-9","article-title":"Remote monitoring of rheumatoid arthritis (REMORA): study protocol for a stepped wedge cluster randomized trial and process evaluation of an integrated symptom tracking intervention","volume":"25","author":"van der Veer","year":"2024","journal-title":"Trials"},{"issue":"1","key":"10.1016\/j.berh.2026.102125_bib98","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/S2665-9913(24)00186-3","article-title":"Digital health technologies to strengthen patient-centred outcome assessment in clinical trials in inflammatory arthritis","volume":"7","author":"McGagh","year":"2025","journal-title":"Lancet Rheumatol"},{"issue":"8","key":"10.1016\/j.berh.2026.102125_bib99","doi-asserted-by":"crossref","first-page":"781","DOI":"10.3899\/jrheum.2024-0074","article-title":"Clinical validation of digitally acquired clinical data and machine learning models for remote measurement of psoriasis and psoriatic arthritis: a proof-of-concept study","volume":"51","author":"Webster","year":"2024","journal-title":"J Rheumatol"},{"key":"10.1016\/j.berh.2026.102125_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103243","article-title":"European advances in digital rheumatology: explainable insights and personalized digital health tools for psoriatic arthritis","volume":"84","author":"Hadjileontiadis","year":"2025","journal-title":"eClinicalMedicine"},{"issue":"4","key":"10.1016\/j.berh.2026.102125_bib101","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004699","article-title":"Digital biomarkers for psoriatic arthritis: a qualitative focus group study on patient-perceived opportunities and barriers","volume":"10","author":"de Groot","year":"2024","journal-title":"RMD Open"}],"container-title":["Best Practice & Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694226000100?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694226000100?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T08:14:04Z","timestamp":1793607244000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694226000100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":101,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1521694226000100"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2026.102125","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical assessment of Psoriatic Arthritis","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2026.102125","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2026 Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102125"}}